One bug, many drugs

K. Hillson (Great Kingshill, United Kingdom)

Source: Virtual Congress 2021 – CCC Paediatric respiratory diseases
Session: CCC Paediatric respiratory diseases
Session type: Challenging clinical cases
Number: 1176

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Hillson (Great Kingshill, United Kingdom). One bug, many drugs. Virtual Congress 2021 – CCC Paediatric respiratory diseases

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
New (or old?) drugs for bad bugs
Source: International Congress 2015 – Antibiotic resistance in respiratory infections
Year: 2015

Allergenicity of wasps and mites used for biological control in greenhouses
Source: Eur Respir J 2005; 26: Suppl. 49, 598s
Year: 2005

Allergenicity of the predator mites Amblyseius cucumeris and Phytoseiulus persimilis
Source: Annual Congress 2008 - COPD and other environment-related lung diseases
Year: 2008

New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005

Pulmonary infections: what to do when it's a bug that you do not know
Source: Eur Respir J 2003; 21: 201
Year: 2003

The side-effects of TB therapy: myth and reality
Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties
Year: 2005

Unlicensed and off-label prescription of respiratory drugs to children
Source: Eur Respir J 2004; 23: 310-313
Year: 2004

A new treatment (Passion fruit) for asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006

Is iroko (chlorophora excelsa) a sensitizing wood at the work place?
Source: Eur Respir J 2001; 18: Suppl. 33, 282s
Year: 2001

New and repurposed drugs
Source: Eur Respir Monogr 2018; 82: 179-204
Year: 2018

High rates of resistance to second line drugs are routinely encountered in Mumbai,India for XDR-TB;highlighting the need for new agents.
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017

How France has hijacked tobacco price increase, an effective tool of tobacco control, to increase the financial profits
Source: Annual Congress 2012 - Tobacco use and cessation
Year: 2012

Rational use of tuberculosis drugs to prevent the development of drug resistance
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012

Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance
Source: Eur Respir J 2012; 39: 802-804
Year: 2012

Medical surveillance of workers exposed to mites and moths in a biological pesticides plant
Source: Annual Congress 2013 –Occupational respiratory diseases: obstructive, interstitial lung diseases and methods of diagnosis
Year: 2013

Occurrence of dust lice species (Psocoptera) in German urban dwellings
Source: Eur Respir J 2001; 18: Suppl. 33, 435s
Year: 2001

Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey
Source: Eur Respir J 2015; 45: 1081-1088
Year: 2015